The global In Vitro Diagnostics market size was valued at USD 69.6 billion in 2018 and is estimated to register a CAGR of 4.75% from 2019 to 2026. Growing geriatric population, which is susceptible to various diseases and requires regular diagnostic tests, is expected to be one of the high impact rendering drivers for the market. Furthermore, new product launch and technological developments, in terms of cost-effectiveness, accuracy, and portability, are expected to propel the market growth over the forecast years.
For instance, in December 2018, Novacyt launched its new CE-IVD mark molecular diagnostic kits called Genesig Real-Time PCR Epstein-Barr Virus (EBV) Kit and Genesig Real-Time PCR BK virus (BKV) Kit. In addition, in July 2018, Surmodics, Inc., launched an assay “MatrixGuard Diluent” to reduce false positive results in IVD tests. Rising prevalence of various diseases, such as cancer, autoimmune diseases, and inflammatory diseases, is expected to drive the demand for IVD testing.
For instance, according to National Institute of Health (NIH), in 2017, approximately 23.5 Million cases of autoimmune diseases were reported in America and this number is expected to increase over the forecast period. Increasing tobacco and alcohol consumption, sedentary lifestyle, unhealthy dietary habits, etc. are the major factors responsible for increased prevalence of cancer. The number of cancer cases is expected to increase in low- and middle-income countries owing to lack of advanced healthcare infrastructure and availability of resources.
Rising demand for Point-of-Care (PoC) devices is expected to fuel the market growth further. In addition, introduction of advanced technologies, such as biochips and nano-biotechnology, and miniaturization of microfluidics are expected to increase the demand for PoC products. These advancements have enabled easy access to PoC diagnostic tests and are likely to facilitate quick and effective test results, thereby boosting the overall market growth.
On the basis of product, the market is segmented into instruments, reagents, and services. Reagents was the dominant product segment in 2018 due to high usage of these products in IVD testing. Rise in the number of R&D initiatives related to reagents and demand for self-test and PoC devices are also likely to boost the segment growth. On the other hand, instruments are expected to witness the highest CAGR during the forecast period. In April 2018, Altona Diagnostics GmbH, launched a CE-IVD marked AltoStar Molecular Diagnostics Workflow. It is a flexible and efficient automatic system that automates the entire workflow from sample preparation till analysis.
On the basis of technology, market is segmented into immunoassay, clinical chemistry, hematology, molecular diagnostics, microbiology, coagulation, and others. Immunoassay led global market in 2018. Increasing incidence of chronic and communicable diseases and rising need for early diagnosis are the key factors attributed to the largest share of this technology segment. Molecular diagnostics is expected to witness the fastest CAGR over the forecast period. Molecular diagnostics enables early detection of cancer, infectious diseases, and genetic disorders by using genetic technologies and has applications in detection of abnormalities in the prenatal stage.
On the basis of application, the market is segmented into infectious disease, cardiology diabetes, cancer, drug testing, nephrology, autoimmune diseases, and others. The infectious disease segment dominated the market with a revenue of around USD 17 billion in 2018. Oncology is expected to be the fastest-growing application segment during the forecast years. The segment is driven by several factors, such as increasing demand for self-care devices and POC diagnostics, for the treatment of chronic diseases.
On the basis of end use, the market is segmented into hospitals, laboratories, home care, and others. IVD services are used by hospitals and laboratories as well as directly by patients.
Hospitals segment accounted for the largest share of 45.68% in 2018, owing to high demand for IVD tests as a result of rise in hospitalization, whereas homecare is expected to be the fastest-growing segment over the forecast period.
North America held the largest market share of 46.23% in 2018. Favorable government regulations, well-established diagnostic infrastructure, technological advancements, and presence of key market participants in this region are the factors responsible for its largest share.
On the other hand, Asia Pacific is expected to witness the fastest growth over the forecast period. Presence of target population base and rapidly improving healthcare infrastructure in Asia Pacific are anticipated to boost the market growth over the next few years.
Some of the key companies in the global market are Siemens Healthineers; Qiagen; Becton, Dickinson and Company; F. Hoffmann-La Roche Ltd.; bioMerieux SA; Hologic, Inc. (Gen-Probe); Abbott Laboratories; Danaher Corp.; Sysmex Corp.; and Cepheid, Inc.
These companies focus on strategies, such as M&A, collaborations, and new product developments to strengthen their global reach and increase market share. For instance, in August 2018, Sysmex Corp. and JVCKENWOOD Corp. jointly established a new company “Creative Nanosystems Corp.” to develop and manufacture biodevices.
|
Attribute |
Details |
|
Base year for estimation |
2018 |
|
Actual estimates/Historical data |
2014 - 2017 |
|
Forecast period |
2019 - 2026 |
|
Market representation |
Revenue in USD Million and CAGR from 2018 to 2026 |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, and MEA |
|
Country scope |
U.S., Canada, U.K., Germany, Spain, France, Italy, Russia, Japan, China, India, South Korea, Singapore, Australia, Brazil, Mexico, Argentina, South Africa, UAE, and Saudi Arabia |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
|
15% free customization scope(equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global In Vitro Diagnostics (IVD) market report on the basis of product, technology, application, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2026)
Instruments
Reagents
Services
Technology Outlook (Revenue, USD Million, 2014 - 2026)
Immunolo
Instruments
Reagents
Services
Hematology
Instruments
Reagents
Services
Clinical Chemistry
Instruments
Reagents
Services
Molecular Diagnostics
Instruments
Reagents
Services
Coagulation
Instruments
Reagents
Services
Microbiology
Instruments
Reagents
Services
Others
Instruments
Reagents
Services
Application Outlook (Revenue, USD Million, 2014 - 2026)
Infectious Disease
Diabetes
Oncology
Cardiology
Nephrology
Autoimmune Diseases
Drug Testing
Others
End Use Outlook (Revenue, USD Million, 2014 - 2026)
Hospitals
Laboratories
Home Care
Others
Regional Outlook (Revenue, USD Million, 2014 - 2026)
North America
U.S.
Canada
Europe
U.K.
Germany
Spain
France
Italy
Russia
Asia Pacific
Japan
China
India
South Korea
Singapore
Australia
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
United Arab Emirates
Saudi Arabia
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
